Stereotactic body radiotherapy to defer systemic therapy in patients with oligorecurrent disease
Jonas Willmann(University of North Texas), Nicolaus Andratschke(University Hospital of Zurich), Sebastian M. Christ(University of Zurich), Maiwand Ahmadsei(University Hospital of Zurich), Eugenia Vlaskou Badra(University Hospital of Zurich), Selma Adilovic(University of Zurich), Michael Mayinger(University Hospital of Zurich), Matthias Gückenberger(University of Zurich)
Cited by 11
Related Papers
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
|Annals of Oncology|2021|577